Research
Hormonal
GLP-1 receptor agonists (liraglutide, semaglutide) mitigate cardiovascular risks and may reduce atherosclerosis through anti-inflammatory mechanisms.
For patients with type 2 diabetes or cardiovascular disease, GLP-1 receptor agonists like liraglutide and semaglutide offer additional benefits beyond weight loss, including reduced cardiovascular risk and potential mitigation of atherosclerosis through anti-inflammatory effects.
StrongSupportsHIGH confidence
it has been proved that liraglutide and semaglutide can mitigating cardiovascular risks (Fig. 1) (Marso et al 2016; Wilding et al. 2021), and may mitigate atherosclerosis through anti-inflammatory mechanisms(Rakipovski et al 2018).
Why this rating
Cites major trials (Marso 2016, Wilding 2021) and mechanistic studies (Rakipovski 2018).
Source
The transformative breakthroughs in GLP-1 research recognized by the 2024 Lasker~DeBakey award
Yu-Fei Zhou et al. · Current Medicine · 2024
DOI 10.1007/s44194-024-00041-w
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (e.g., liraglutide, semaglutide) induce significant weight loss in individuals with obesity by suppressing appetite and reducing energy intake through central nervous system mechanisms.Strong
- Multi-receptor agonists (tirzepatide, retatrutide) and oral GLP-1 receptor agonists (orforglipron) are emerging treatments that reduce body weight and improve metabolic health.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →